SUPPLEMENTAL MATERIALS

Apoptotic ablation of platelets reduces atherosclerosis in mice with diabetes

Man K.S. Lee[1,2,5*], Michael J. Kraakman[1*], Dragana Dragoljevic[1,5], Nordin M.J. Hanssen[1,2,7,8], Michelle C. Flynn[1,3], Annas Al-Sharea[1], Gopalkrishna Sreejit[9], Camilla Bertuzo-Veiga[1,6], Olivia D. Cooney[1,2], Fatima Baig[1], Elizabeth Morriss[1], Mark E. Cooper[2], Emma C. Josefsson[10,11], Benjamin T. Kile[4,12], Prabhakara R. Nagareddy[9*], and Andrew J. Murphy[1,3,5,6*]

[1]Haematopoiesis and Leukocyte Biology, Baker Heart and Diabetes Institute, Melbourne 3004, Australia
[2]Department of Diabetes, [3]Department of Immunology, [4]Monash Biomedicine Discovery Institute Monash University, Melbourne, Australia
[5]Department of Cardiometabolic Health, [6]Department of Physiology, University of Melbourne, Melbourne, Australia
[7]Department of internal Medicine, CARIM, School of cardiovascular diseases, Maastricht University, Maastricht, The Netherlands
[8]Amsterdam Diabetes Centrum, Internal and vascular medicine, Amsterdam UMC, AMC, The Netherlands
[9]Division of Cardiac Surgery, Dept. of Surgery, Ohio State University, Columbus, Ohio, USA
[10]The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
[11]Department of Medical Biology; University of Melbourne; Melbourne, VIC, Australia
[12]Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia

Supplementary Figure I. Dose frequency of ABT-737. Diabetic (STZ) *Apoe*-/- mice were treated with ABT-737 (30mg/kg i.p.) tri- or bi-weekly and platelets we calculated as a percentage of control (non-diabetic *Apoe*-/- mice). n=3/group.

Supplementary Figure II. Atherosclerotic plaque smooth muscle cells. Atherosclerotic plaques were assessed in the aortic sinus for smooth muscle cell content. **A)** Representative images of and **B)** quantification of smooth muscle cell α-actin. Data are presented mean ± SEM and analyzed using a one-way ANOVA followed by a Dunnett's multiple comparisons test, biological replicates, n=7, 6, 7/group; *p<0.05, **p<0.01 *c.f.* control, or as indicated.

Major Resources Table

Animals (in vivo studies)

Species	Vendor or Source	Background Strain	Sex
Mouse	In-house generated	*Ldlr$^{+/-}$ (C57Bl/6J background)*	M
Mouse	Jax stock #002052	*Apoe$^{-/-}$(C57Bl/6J background)*	M
Mouse	In-house generated	*Bcl-x^{PLT20}(C57Bl/6J background)*	M

Genetically Modified Animals – Generating *Ldlr$^{+/-}$* mice

	Species	Vendor or Source	Background Strain
Parent - Male	Mouse	Jax stock #002207	*Ldlr$^{-/-}$(C57Bl/6J background)*
Parent - Female	Mouse	Jax stock #000664	C57Bl/6J

Antibodies

Target antigen	Vendor or Source	Catalog #	Working concentration
CD45R	Biolegend	103205	1:400
CD19	Biolegend	152403	1:400
CD11b	Biolegend	101211	1:400
CD3e	eBioscience	11-0031-82	1:400
TER-119	Biolegend	116215	1:400
CD2	Biolegend	100105	1:400
CD8a	Invitrogen	11-0081-85	1:400
CD4	eBioscience	11-0042-85	1:400
Ly6-C/G	Biolegend	553127	1:400
Sca1	Biolegend	108120	1:400
cKit	Biolegend	105826	1:400
CD34	Biolegend	119309	1:400
FcγRII/III	BD Biosciences	560540	1:400
CD45	Biolegend	103126	1:400
CD115	eBioscience	12-1152-82	1:400
Gr1	BD Bioscience	553127	1:400
CD41	Invitrogen	17-0411-82	1:400

Other

Description	Source / Repository
ABT-737	Abbvie